engleski

Azithromycin efficacy in the treatment of patients with erysipelas - a pilot study

The aim of this research was to investigate the efficacy of parenteral azithromycin in the treatment of erysipelas. In the period from January 1, 2001 until August 31, 2001, we examined a total of 42 patients with erysipelas, of whom 10 had facial erysipelas and 32 erysipelas on lower legs and feet. Study inclusion criteria were as follows: hospitalized patients older than 18 years of age, fever > 37, 5°C, leukocytosis > 10x109/L with neutrophilia, the presence of at least two of the following signs or symptoms: redness, swelling, pruritis, burning, regional lymphangitis/lymphadenitis. Patients who received antimicrobial therapy within 48 hours prior to their enrolment, patients with lower extremity varicosity, with ulcus cruris, pregnant and lactating women were excluded from the study. Azithromycin was administered in dosage of 1x500 mg iv for 3 days followed by an additional peroral dose of 1x500 mg for 2 days. Clinical efficiency was evaluated 5 days after the beginning of treatment. Treatment results were as follows: cure in 36 (85, 71%), improvement in 3 (7, 14%), and failure in 3 (7, 14%) patients. No drug adverse events were recorded during the administration of therapy.

Azithromycin; erysipel

nije evidentirano